Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

NACompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Coronary Artery DiseaseAcute Coronary Syndrome
Interventions
DRUG

Ticagrelor 180mg

"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"

DRUG

Prasugrel 10mg

"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"

DRUG

Ticagrelor 90mg

"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
lead

University of Florida

OTHER

NCT02016170 - Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor | Biotech Hunter | Biotech Hunter